Cost minimization and budget impact analysis of rituximab versus infliximab, adalimumab, etanercept and abatacept in rheumatoid arthritis from a payer perspective in Brazil

被引：0
|
作者：
Saggia, M. G. [1 ]
Santos, E. A. [1 ]
Nasciben, V [1 ]
机构：
[1] Roche Brazil, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70821-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A260 / A260
页数：1
相关论文
共 50 条
  • [11] Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
    Malottki, K.
    Barton, P.
    Tsourapas, A.
    Uthman, A. O.
    Liu, Z.
    Routh, K.
    Connock, M.
    Jobanputra, P.
    Moore, D.
    Fry-Smith, A.
    Chen, Y-F
    HEALTH TECHNOLOGY ASSESSMENT, 2011, 15 (14) : 1 - +
  • [12] BUDGET IMPACT OF ETANERCEPT VERSUS ADALIMUMAB FOR TREATMENT OF RHEUMATOID ARTHRITIS IN BIOLOGIC -NAIVE PATIENTS IN THE UNITED KINGDOM
    Onishchenko, K.
    Tarallo, M.
    Curiale, C.
    Alexopoulos, S. T.
    VALUE IN HEALTH, 2018, 21 : S193 - S194
  • [13] Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance
    Bonafede, Machaon
    Watson, Crystal
    Joseph, George
    Princic, Nicole
    Harrison, David J.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S778 - S778
  • [14] BUDGET IMPACT ANALYSIS OF INTRODUCTION OF SUBCUTANEOUS INFLIXIMAB IN FRANCE FROM A PAYER PERSPECTIVE
    Pradie, M.
    Hadjadj, C.
    Moreau, Petiteau F.
    VALUE IN HEALTH, 2022, 25 (01) : S81 - S81
  • [15] Relative cost of etanercept versus infliximab in the treatment of rheumatoid arthritis.
    Sweis, BP
    Ellman, CJ
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S44 - S44
  • [16] COST MINIMIZATION ANALYSIS WITH RITUXIMAB IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS (RA) FROM THE MEXICAN PUBLIC PERSPECTIVE
    Lechuga, D.
    Alva, M.
    VALUE IN HEALTH, 2012, 15 (04) : A40 - A40
  • [17] Cost-effectiveness analysis of etanercept vs infliximab for treatment of severe rheumatoid arthritis in Brazil
    Saggia, M. G.
    Pina, F. P.
    VALUE IN HEALTH, 2006, 9 (06) : A220 - A220
  • [18] ABATACEPT OR INFLIXIMAB FOR RHEUMATOID ARTHRITIS IN VENEZUELA? A COST-EFFECTIVENESS ANALYSIS
    Alfonso-Cristancho, R.
    Serra, N.
    Aiello, E. C.
    Roa, C. N.
    VALUE IN HEALTH, 2011, 14 (03) : A126 - A127
  • [19] Budget Impact of Etanercept Versus Adalimumab for Treatment of Rheumatoid Arthritis in Biologic-Naive Patients in the United Kingdom
    Onishchenko, Kateryna
    Tarallo, Miriam
    Curiale, Cinzia
    Alexopoulos, Stamatia Theodora
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [20] COST PER TREATED RHEUMATOID ARTHRITIS (RA) PATIENT FOR ETANERCEPT, ADALIMUMAB AND INFLIXIMAB: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS
    Bonafede, M.
    Gandra, S. R.
    Watson, C.
    Princic, N.
    Fox, K. M.
    VALUE IN HEALTH, 2012, 15 (04) : A37 - A37
12345